A Note on Safety We built medicinal-use.com to help make sense of the UK’s changing laws, but we aren’t doctors. This content is for research and education—it isn’t medical advice. Before changing your healthcare routine or starting a new treatment, please speak with a GMC-registered clinician. Your safety matters more than any article we write.
Important Disclaimer This article is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment recommendation. Cannabis-based products for medicinal use (CBPMs) are prescription-only medicines in the UK and can only be prescribed by specialist doctors on the GMC Specialist Register. Always consult a qualified healthcare professional before considering any treatment. Laws, guidelines, and evidence evolve; check official sources (GMC, NICE, MHRA, Home Office) for the latest. Use of this site is at your own risk.
Chronic pain affects an estimated 35–51% of the UK population and is one of the leading reasons people seek medical cannabis prescriptions in 2025. While NHS access remains extremely limited, private specialist clinics have prescribed CBPMs to thousands of patients with chronic pain conditions where conventional treatments have failed or caused intolerable side effects.
This guide summarizes current evidence, typical access routes, and key considerations.
1. What Is Chronic Pain and Why Consider CBPMs?
Chronic pain is defined as pain lasting longer than 3 months. It includes neuropathic pain (nerve damage), nociplastic pain (altered pain processing), and musculoskeletal pain (e.g., arthritis, fibromyalgia, back pain).
Conventional treatments (NSAIDs, gabapentinoids, antidepressants, opioids, physiotherapy) often provide limited relief or come with side effects (e.g., opioid dependence, gastrointestinal issues). CBPMs (containing THC and/or CBD) interact with the endocannabinoid system to potentially reduce pain perception, inflammation, and associated symptoms like sleep disturbance and anxiety.
2. NHS vs Private Access for Chronic Pain in 2025
| Aspect | NHS Route | Private Clinic Route |
|---|---|---|
| Eligibility | Extremely narrow; NICE does not recommend CBPMs for chronic primary/secondary pain due to insufficient evidence | Broader: treatment-resistant chronic pain (2+ conventional treatments failed) |
| Common Prescriptions | Rare; mostly licensed products like Sativex (for MS spasticity) | Oils, capsules, flower (vaporised) – THC/CBD balanced or THC-dominant |
| Cost | Free if approved (almost never happens) | Consultation £50–£200; meds £50–£400+/month |
| Waiting Time | Months/years for referral | Days to weeks |
| Evidence Required | High-quality RCTs (limited for chronic pain) | Real-world data + specialist judgement |
In practice, ~99% of CBPM prescriptions for chronic pain are private in 2025.
3. What the Evidence Shows in 2025
- Real-World Data UK Medical Cannabis Registry (largest ongoing UK dataset) and patient reports show associations between CBPMs and reduced pain severity/interference, improved sleep, and better quality of life in chronic pain patients. Many studies note 60–80% of private patients cite chronic pain as primary condition.
- NICE Guidelines NICE (NG144 and chronic pain guideline) does not recommend CBPMs for routine chronic pain management due to low/moderate-quality evidence from RCTs. Cochrane reviews find limited good evidence for neuropathic pain relief.
- Other Evidence Meta-analyses and observational data suggest small to moderate pain reductions, especially with non-inhaled CBPMs. Inhaled products (flower/vape) are common in UK private practice but have less RCT support. Benefits often include reduced opioid use and improved anxiety/sleep.
- Limitations Many studies are underpowered or short-term. Long-term safety (dependence, psychiatric effects with high THC) needs more research. Evidence is stronger for specific neuropathic/MS pain than widespread chronic primary pain.
4. How Patients Access CBPMs for Chronic Pain
Step-by-Step (Private Route – Most Common)
- Self-refer to a CQC-regulated private clinic (e.g., Releaf, Alternaleaf, Mamedica, Curaleaf, Lyphe).
- Online eligibility check (upload history, past treatments).
- Specialist consultation (£50–£200).
- If suitable: Tailored prescription (e.g., balanced THC/CBD oil, THC flower).
- Medication from specialist pharmacy (home delivery).
- Follow-ups (1–3 months) for adjustments.
Typical Costs
- Consultation: £50–£200
- Medication: £50–£400+/month (varies by dose/form)
- Many clinics offer payment plans.
5. Important Legal & Safety Notes
- CBPMs are Schedule 2 controlled drugs – possession without prescription is illegal.
- Driving: Strict DVLA rules – impairment windows apply (separate guide needed).
- Risks: THC can cause dependence, psychiatric effects, interactions. CBD generally safer but less studied for pain.
- No guarantee of benefit – individual response varies.
- Always carry prescription and original packaging.
Sources
- NICE NG144 & Chronic Pain Guideline
- UK Medical Cannabis Registry patient data summaries (2024–2025)
- GMC guidance on unlicensed CBPMs
- Cochrane reviews on cannabinoids for chronic/neuropathic pain
- Private clinic reports (Releaf, Alternaleaf, Curaleaf, etc.)